|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics: CA Cancer. J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Gansler T, Ganz PA, Grant M, Greene FL,
Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et
al: Sixty years of CA: A cancer journal for clinicians. CA Cancer J
Clin. 60:345–350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang CW, Tsai HL, Chen YT, Huang CM, Ma
CJ, Lu CY, Kuo CH, Wu DC, Chai CY and Wang JY: The prognostic
values of EGFR expression and KRAS mutation in patients with
synchronous or metachronous metastatic colorectal cancer. BMC
Cancer. 13:5992013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cunningham D, Pyrhönen S, James RD, Punt
CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham
CA, Awad L, et al: Randomised trial of irinotecan plus supportive
care versus supportive care alone after fluorouracil failure for
patients with metastatic colorectal cancer. Lancet. 352:1413–1418.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karoui M, Roudot-Thoraval F, Mesli F,
Mitry E, Aparicio T, Des Guetz G, Louvet C, Landi B, Tiret E and
Sobhani I: Primary colectomy in patients with stage IV colon cancer
and unresectable distant metastases improves overall survival:
Results of a multicentric study. Dis Colon Rectum. 54:930–938.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Platell C, Ng S, O'Bichere A and Tebbutt
N: Changing management and survival in patients with stage IV
colorectal cancer. Dis Colon Rectum. 54:214–219. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kleespies A, Füessl KE, Seeliger H,
Eichhorn ME, Müller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME
and Jauch KW: Determinants of morbidity and survival after elective
non-curative resection of stage IV colon and rectal cancer. Int J
Colorectal Dis. 24:1097–1109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hollis M, Nair K, Vyas A, Chaturvedi LS,
Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer:
Early detection, prognosis, and chemosensitivity. World J
Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Juliano R: Movin' on through with Cdc2.
Nat Cell Biol. 5:589–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Manes T, Zheng DQ, Tognin S, Woodard AS,
Marchisio PC and Languino LR: Alpha(v)beta3 integrin expression
up-regulates cdc2, which modulates cell migration. J Cell Biol.
161:817–826. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyagaki H, Yamasaki M, Miyata H,
Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Fujiwara Y, Ishii
H, Tanaka F, et al: Overexpression of PFTK1 predicts resistance to
chemotherapy in patients with oesophageal squamous cell carcinoma.
Br J Cancer. 106:947–954. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pang EY, Bai AH, To KF, Sy SM, Wong NL,
Lai PB, Squire JA and Wong N: Identification of PFTAIRE protein
kinase 1, a novel cell division cycle-2 related gene, in the motile
phenotype of hepatocellular carcinoma cells. Hepatology.
46:436–445. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang T and Chen JY: Identification and
cellular localization of human PFTAIRE1. Gene. 267:165–172. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leung WK, Ching AK, Chan AW, Poon TC, Mian
H, Wong AS, To KF and Wong N: A novel interplay between oncogenic
PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of
liver cancer cell motility. Oncogene. 30:4464–4475. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu X, Wang Y, Wang H, Ni Q, Zhang C, Zhu
J, Huang W, Xu P, Mao G and Yang S: Upregulated PFTK1 promotes
tumor cell proliferation, migration, and invasion in breast cancer.
Med Oncol. 32:1952015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang L, Zhu J, Huang H, Yang Q, Cai J,
Wang Q, Zhu J, Shao M, Xiao J, Cao J, et al: PFTK1 promotes gastric
cancer progression by regulating proliferation, migration and
invasion. PLoS One. 10:e01404512015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan S, Zhao C, Zhang L, Dai S, Ren J,
Zhang X, Ban N, He X, Yang L, Bao Z, et al: Knockdown of PFTK1
inhibits the migration of glioma cells. J Mol Neurosci. 57:257–264.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai M, Al-Odaini AA, Fils-Aimé N,
Villatoro MA, Guo J, Arakelian A, Rabbani SA, Ali S and Lebrun JJ:
Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast
cancer cell migration and tumor local invasion. Breast Cancer Res.
15:R492013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Novak J and Fabian P: Comments on the TNM
classification of malignant tumours-7th edition. Klin Onkol.
24:149–150. 2011.(In Czech). PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun R, Wang X, Zhu H, Mei H, Wang W, Zhang
S and Huang J: Prognostic value of LAMP3 and TP53 overexpression in
benign and malignant gastrointestinal tissues. Oncotarget.
5:12398–12409. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang J, Zhang X, Tang Q, Zhang F, Li Y,
Feng Z and Zhu J: Prognostic significance and potential therapeutic
target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol.
64:343–348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Poomsawat S, Buajeeb W, Khovidhunkit SO
and Punyasingh J: Alteration in the expression of cdk4 and cdk6
proteins in oral cancer and premalignant lesions. J Oral Pathol
Med. 39:793–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakayama S, Torikoshi Y, Takahashi T,
Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K,
Hortobagyi GN, et al: Prediction of paclitaxel sensitivity by CDK1
and CDK2 activity in human breast cancer cells. Breast Cancer Res.
11:R122009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim SJ, Nakayama S, Miyoshi Y, Taguchi T,
Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara
H and Noguchi S: Determination of the specific activity of CDK1 and
CDK2 as a novel prognostic indicator for early breast cancer. Ann
Oncol. 19:68–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hansel DE, Dhara S, Huang RC, Ashfaq R,
Deasel M, Shimada Y, Bernstein HS, Harmon J, Brock M, Forastiere A,
et al: CDC2/CDK1 expression in esophageal adenocarcinoma and
precursor lesions serves as a diagnostic and cancer progression
marker and potential novel drug target. Am J Surg Pathol.
29:390–399. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Semczuk A and Jakowicki JA: Alterations of
pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial
carcinogenesis. Cancer Lett. 203:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Simon R, Struckmann K, Schraml P, Wagner
U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ,
et al: Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI)
in urinary bladder cancer. Oncogene. 21:2476–2483. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marone M, Scambia G, Giannitelli C,
Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P and
Mancuso S: Analysis of cyclin E and CDK2 in ovarian cancer: Gene
amplification and RNA overexpression. Int J Cancer. 75:34–39. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mihara M, Shintani S, Nakahara Y, Kiyota
A, Ueyama Y, Matsumura T and Wong DT: Overexpression of CDK2 is a
prognostic indicator of oral cancer progression. Jpn J Cancer Res.
92:352–360. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yue W, Zhao X, Zhang L, Xu S, Liu Z, Ma L,
Jia W, Qian Z, Zhang C, Wang Y and Yang X: Cell cycle protein
cyclin Y is associated with human non-small-cell lung cancer
proliferation and tumorigenesis. Clin Lung Cancer. 12:43–50. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang HJ, Wang L, Wang M, Ma SP, Cheng BF,
Li ZC and Feng ZW: Serine/threonine-protein kinase PFTK1 modulates
oligodendrocyte differentiation via PI3K/AKT pathway. J Mol
Neurosci. 55:977–984. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mullen AR and DeBerardinis RJ:
Genetically-defined metabolic reprogramming in cancer. Trends
Endocrinol Metab. 23:552–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
